Precision oncology is tailoring treatments based on molecular profiles, while new surgical and radiotherapy methods boost recovery. Despite challenges like late diagnosis and high treatment costs, ...

A targeted cancer therapy from partners AstraZeneca and Daiichi Sankyo met a key goal in a pivotal lung cancer study, but the companies also revealed an unspecified number of patient deaths, clouding ...

Daiichi Sankyo (TSE:4568) posted 11.8% earnings growth over the last twelve months, trailing its 32.7% average from the past five years. Net profit margin edged down to 14.1% from 14.2% a year ago.

Presented at the European Society for Medical Oncology, study results showed Datroway extended survival in breast cancer ...

The multicentre, randomised trial was conducted in China, but Sichuan-Kelun and Merck & Co will commercialise sac-TMT in ...

These pivotal studies investigated AstraZeneca and Daiichi Sankyo’s Enhertu, a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate with a topoisomerase II-targeting ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the ...

After a string of new approvals, Daiichi Sankyo is boosting sales projection for AstraZeneca-partnered star cancer drug Enhertu. Daiichi now expects Enhertu could reach sales of 195.2 billion Japanese ...

TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen.

Daiichi Sankyo will acquire Ambit Biosciences for up to about $410 million, the companies said today, in a deal that adds Ambit’s lead candidate—the Phase III cancer compound quizartinib—to the ...

Investing.com - Daiichi Sankyo stock fell 4.5% on Friday after the Japanese pharmaceutical company maintained its core operating profit target at ¥350 billion despite strong sales performance.

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is teaming up with independent research institute BioMed X to form a new research ...